683 related articles for article (PubMed ID: 32317293)
1. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
2. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.
Lopes JE; Sun L; Flick HL; Murphy EA; Losey HC
J Pharmacol Exp Ther; 2021 Nov; 379(2):203-210. PubMed ID: 34362793
[TBL] [Abstract][Full Text] [Related]
5. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
6. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.
Chen X; Ai X; Wu C; Wang H; Zeng G; Yang P; Liu G
Cell Death Dis; 2018 Sep; 9(10):989. PubMed ID: 30250191
[TBL] [Abstract][Full Text] [Related]
7. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
Krieg C; Létourneau S; Pantaleo G; Boyman O
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11906-11. PubMed ID: 20547866
[TBL] [Abstract][Full Text] [Related]
8. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
[TBL] [Abstract][Full Text] [Related]
9. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
[TBL] [Abstract][Full Text] [Related]
10. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
11. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
12. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Vazquez-Lombardi R; Loetsch C; Zinkl D; Jackson J; Schofield P; Deenick EK; King C; Phan TG; Webster KE; Sprent J; Christ D
Nat Commun; 2017 May; 8():15373. PubMed ID: 28497796
[TBL] [Abstract][Full Text] [Related]
13. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
14. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
Merchant R; Galligan C; Munegowda MA; Pearce LB; Lloyd P; Smith P; Merchant F; To MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058325
[TBL] [Abstract][Full Text] [Related]
15. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.
Su EW; Moore CJ; Suriano S; Johnson CB; Songalia N; Patterson A; Neitzke DJ; Andrijauskaite K; Garrett-Mayer E; Mehrotra S; Paulos CM; Doedens AL; Goldrath AW; Li Z; Cole DJ; Rubinstein MP
Sci Transl Med; 2015 Oct; 7(311):311ra170. PubMed ID: 26511507
[TBL] [Abstract][Full Text] [Related]
16. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
[TBL] [Abstract][Full Text] [Related]
17. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
LaPorte KM; Hernandez R; Santos Savio A; Malek TR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
[TBL] [Abstract][Full Text] [Related]
18. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
19. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
20. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.
Meghnem D; Morisseau S; Frutoso M; Trillet K; Maillasson M; Barbieux I; Khaddage S; Leray I; Hildinger M; Quéméner A; Jacques Y; Mortier E
J Immunol; 2017 Jun; 198(12):4563-4568. PubMed ID: 28507024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
